the University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners recently announced the launch of Magnolia Neurosciences Corporation – a biopharmaceutical company advancing a new class of neuroprotective medicines.Read More
New tools are enabling researchers to explore individual cells with unprecedented clarity, allowing RNA and protein expression levels to be simultaneously analyzed. In this blog, Brian Lilhanand, Global Platform Leader, Single Cell Multiomics, at BD, discusses how BD’s new AbSeq Assay can provide this targeted profiling and benefit immunology researchers.
Electronic Laboratory Notebooks are becoming more popular as labs embrace digitization. ELN provider Biodata’s flagship offering, Labguru, has over 30,000 users worldwide. We caught up with Steve Yemm, recently appointed CEO of BioData, to ask him about the advantages of ELNs and the challenges they face in a digital market.
Many Chinese microfluidics companies are emerging and expanding, and it could be game-changing for the industry. We spoke with Yole Développement analyst, Sébastien Clerc, to learn more.Read More
Earlier this summer, the Rare Genomics Institute announced the winners of the 2018 BeHEARD (Help Empower & Accelerate Research Discoveries) Challenge. The Challenge tasks researchers or foundations working in fields of rare disease research to apply for grants, either financial or technological, to assist their research. We caught up with the Institute’s Arvin M. Gouw to discuss the awards and the battle against rare disease.Read More
Degenerative disc diseases are debilitating, and treatment options are lacking. Three leaders from Discgenics explain how they are harnessing the restorative potential of cells native to the intervertebral disc to alleviate lower back pain.Read More
The failure of conventional antibiotics to treat numerous antibiotic-resistant infections necessitates the development of new agents – as a natural anti-microbial nitric oxide holds particular promise.Read More
We recently spoke to Dr. Hervé Perron, HDR, Chief Scientific Officer at GeNeuro to learn about their progress developing new treatments for neurological and autoimmune diseases associated with pathogenic proteins expressed by human endogenous retroviruses (HERVs).Read More